RU2729725C2 - Системы или устройства и способы проведения диализа - Google Patents
Системы или устройства и способы проведения диализа Download PDFInfo
- Publication number
- RU2729725C2 RU2729725C2 RU2018135326A RU2018135326A RU2729725C2 RU 2729725 C2 RU2729725 C2 RU 2729725C2 RU 2018135326 A RU2018135326 A RU 2018135326A RU 2018135326 A RU2018135326 A RU 2018135326A RU 2729725 C2 RU2729725 C2 RU 2729725C2
- Authority
- RU
- Russia
- Prior art keywords
- fluid
- dialysis
- balancing
- container
- dialysate
- Prior art date
Links
- 238000000502 dialysis Methods 0.000 title claims abstract description 417
- 238000000034 method Methods 0.000 title claims abstract description 126
- 239000012530 fluid Substances 0.000 claims abstract description 573
- 239000013060 biological fluid Substances 0.000 claims abstract description 219
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 163
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 161
- 239000000385 dialysis solution Substances 0.000 claims abstract description 156
- 239000000126 substance Substances 0.000 claims abstract description 149
- 238000005303 weighing Methods 0.000 claims abstract description 122
- 239000003053 toxin Substances 0.000 claims abstract description 94
- 231100000765 toxin Toxicity 0.000 claims abstract description 94
- 230000027455 binding Effects 0.000 claims abstract description 82
- 239000003463 adsorbent Substances 0.000 claims abstract description 51
- 239000000243 solution Substances 0.000 claims abstract description 48
- 239000012528 membrane Substances 0.000 claims abstract description 41
- 230000002829 reductive effect Effects 0.000 claims abstract description 24
- 238000004364 calculation method Methods 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 238000009825 accumulation Methods 0.000 claims abstract description 5
- 210000004369 blood Anatomy 0.000 claims description 82
- 239000008280 blood Substances 0.000 claims description 82
- 239000011230 binding agent Substances 0.000 claims description 74
- 102000009027 Albumins Human genes 0.000 claims description 69
- 108010088751 Albumins Proteins 0.000 claims description 69
- 239000002253 acid Substances 0.000 claims description 58
- 238000010438 heat treatment Methods 0.000 claims description 44
- 238000001914 filtration Methods 0.000 claims description 23
- 238000011026 diafiltration Methods 0.000 claims description 18
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 238000006073 displacement reaction Methods 0.000 claims description 5
- 208000019423 liver disease Diseases 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 206010019663 Hepatic failure Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 208000007903 liver failure Diseases 0.000 claims description 2
- 231100000835 liver failure Toxicity 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 6
- 108700012359 toxins Proteins 0.000 description 90
- 238000011069 regeneration method Methods 0.000 description 86
- 230000008929 regeneration Effects 0.000 description 85
- 239000012141 concentrate Substances 0.000 description 75
- 238000001784 detoxification Methods 0.000 description 43
- 239000002585 base Substances 0.000 description 42
- 238000004891 communication Methods 0.000 description 40
- 238000010790 dilution Methods 0.000 description 35
- 239000012895 dilution Substances 0.000 description 35
- 239000002699 waste material Substances 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 33
- 239000000706 filtrate Substances 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 238000011282 treatment Methods 0.000 description 29
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 26
- 238000001816 cooling Methods 0.000 description 25
- 238000000108 ultra-filtration Methods 0.000 description 24
- 230000002378 acidificating effect Effects 0.000 description 22
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 22
- 230000001965 increasing effect Effects 0.000 description 22
- 239000012466 permeate Substances 0.000 description 22
- 238000005259 measurement Methods 0.000 description 21
- 102000008100 Human Serum Albumin Human genes 0.000 description 19
- 108091006905 Human Serum Albumin Proteins 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 238000007792 addition Methods 0.000 description 18
- 238000010586 diagram Methods 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 18
- 230000008569 process Effects 0.000 description 17
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical group C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 16
- -1 aromatic amino acids Chemical class 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- 230000004087 circulation Effects 0.000 description 14
- 239000007789 gas Substances 0.000 description 14
- 210000002381 plasma Anatomy 0.000 description 14
- 238000012545 processing Methods 0.000 description 14
- 239000013543 active substance Substances 0.000 description 12
- 102000014914 Carrier Proteins Human genes 0.000 description 11
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 229960001948 caffeine Drugs 0.000 description 11
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 108010078791 Carrier Proteins Proteins 0.000 description 10
- 238000001631 haemodialysis Methods 0.000 description 10
- 230000000322 hemodialysis Effects 0.000 description 10
- 238000005086 pumping Methods 0.000 description 10
- 150000007513 acids Chemical class 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- 238000005192 partition Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 239000002596 immunotoxin Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003792 electrolyte Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000001172 regenerating effect Effects 0.000 description 6
- 230000003381 solubilizing effect Effects 0.000 description 6
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 5
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 5
- GRUVVLWKPGIYEG-UHFFFAOYSA-N 2-[2-[carboxymethyl-[(2-hydroxyphenyl)methyl]amino]ethyl-[(2-hydroxyphenyl)methyl]amino]acetic acid Chemical compound C=1C=CC=C(O)C=1CN(CC(=O)O)CCN(CC(O)=O)CC1=CC=CC=C1O GRUVVLWKPGIYEG-UHFFFAOYSA-N 0.000 description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000002738 chelating agent Substances 0.000 description 5
- 229960000958 deferoxamine Drugs 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 229960001639 penicillamine Drugs 0.000 description 5
- 230000003134 recirculating effect Effects 0.000 description 5
- FGGPAWQCCGEWTJ-UHFFFAOYSA-M sodium;2,3-bis(sulfanyl)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(S)CS FGGPAWQCCGEWTJ-UHFFFAOYSA-M 0.000 description 5
- ACTRVOBWPAIOHC-XIXRPRMCSA-N succimer Chemical compound OC(=O)[C@@H](S)[C@@H](S)C(O)=O ACTRVOBWPAIOHC-XIXRPRMCSA-N 0.000 description 5
- 229960001124 trientine Drugs 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000003929 acidic solution Substances 0.000 description 4
- 239000012670 alkaline solution Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 229910001431 copper ion Inorganic materials 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 208000007386 hepatic encephalopathy Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000001926 lymphatic effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 210000001179 synovial fluid Anatomy 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 238000002615 hemofiltration Methods 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000001139 pH measurement Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000002441 uremic toxin Substances 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000007485 conventional hemodialysis Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000001272 nitrous oxide Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012959 renal replacement therapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- QWPCKAAAWDCDCW-VKHMYHEASA-N (2s)-2-amino-4-nitrososulfanylbutanoic acid Chemical compound OC(=O)[C@@H](N)CCSN=O QWPCKAAAWDCDCW-VKHMYHEASA-N 0.000 description 1
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 241001535291 Analges Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005253 cladding Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- YQICPRLGRXWDHI-XUDUSOBPSA-N digitoxin(1-) Chemical compound C[C@H]([C@H]([C@H](C1)O)O)O[C@H]1O[C@H]([C@@H](C)O[C@H](C1)O[C@H]([C@@H](C)O[C@H](C2)O[C@@H](CC3)C[C@@H](CC4)[C@@]3(C)[C@@H](CC[C@]3(C)[C@H](CC5)C([CH-]O6)=CC6=O)[C@@H]4[C@]35O)[C@H]2O)[C@H]1O YQICPRLGRXWDHI-XUDUSOBPSA-N 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 238000010889 donnan-equilibrium Methods 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 201000011200 hepatorenal syndrome Diseases 0.000 description 1
- KIWQWJKWBHZMDT-UHFFFAOYSA-N homocysteine thiolactone Chemical compound NC1CCSC1=O KIWQWJKWBHZMDT-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002648 laminated material Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 150000002835 noble gases Chemical class 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000024033 toxin binding Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1603—Regulation parameters
- A61M1/1605—Physical characteristics of the dialysate fluid
- A61M1/1609—Physical characteristics of the dialysate fluid after use, i.e. downstream of dialyser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1621—Constructional aspects thereof
- A61M1/1643—Constructional aspects thereof with weighing of fresh and used dialysis fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
- A61M1/1676—Dialysates therefor containing proteins, e.g. albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1694—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes with recirculating dialysing liquid
- A61M1/1696—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes with recirculating dialysing liquid with dialysate regeneration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3479—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by dialysing the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3482—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3623—Means for actively controlling temperature of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3324—PH measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3368—Temperature
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3379—Masses, volumes, levels of fluids in reservoirs, flow rates
- A61M2205/3393—Masses, volumes, levels of fluids in reservoirs, flow rates by weighing the reservoir
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2016/000287 WO2017158392A1 (en) | 2016-03-14 | 2016-03-14 | Systems or apparatuses and methods for performing dialysis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018135326A RU2018135326A (ru) | 2020-04-15 |
| RU2018135326A3 RU2018135326A3 (enExample) | 2020-04-15 |
| RU2729725C2 true RU2729725C2 (ru) | 2020-08-11 |
Family
ID=55650602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018135326A RU2729725C2 (ru) | 2016-03-14 | 2016-03-14 | Системы или устройства и способы проведения диализа |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11351291B2 (enExample) |
| EP (1) | EP3429657B1 (enExample) |
| JP (1) | JP7011263B2 (enExample) |
| KR (1) | KR20180125489A (enExample) |
| CN (1) | CN109069719B (enExample) |
| AU (1) | AU2016398366B2 (enExample) |
| CA (1) | CA3017435A1 (enExample) |
| DK (1) | DK3429657T3 (enExample) |
| ES (1) | ES2922636T3 (enExample) |
| IL (1) | IL261628B (enExample) |
| MX (1) | MX2018010947A (enExample) |
| PL (1) | PL3429657T3 (enExample) |
| RU (1) | RU2729725C2 (enExample) |
| WO (1) | WO2017158392A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU225627U1 (ru) * | 2023-12-30 | 2024-04-26 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Устройство контура доставки газовоздушной смеси с оксидом азота для аппаратов искусственного кровообращения |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3055809A1 (en) * | 2017-03-28 | 2018-10-04 | Bernhard Kreymann | Compositions and methods for regenerating carrier protein-containing multiple pass albumin dialysis fluid |
| CN108211032B (zh) | 2018-02-01 | 2023-11-17 | 南方医科大学珠江医院 | 组合型生物人工肝支持系统 |
| EP3823689A4 (en) | 2018-07-20 | 2022-03-16 | Fresenius Medical Care Deutschland GmbH | CENTRALLY CONTROLLED MULTI-PATIENT DIALYSIS THERAPY SYSTEM AND THEIR USE |
| EP3626721B1 (en) | 2018-07-31 | 2023-09-06 | Paolo Bonomi | Synthesis of ester and amide derivatives of beta-lactam nuclei |
| US11147907B2 (en) * | 2018-12-10 | 2021-10-19 | Humanity Life Extension Llc | Systems and methods for treating blood |
| JP7154128B2 (ja) * | 2018-12-28 | 2022-10-17 | 日機装株式会社 | 血液浄化装置 |
| FR3091999A1 (fr) * | 2019-01-25 | 2020-07-31 | Mexbrain | Dispositif d’extraction conjointe d’un cation métallique et d’une molécule cible |
| CN110338779B (zh) * | 2019-08-19 | 2023-01-31 | 河南科技大学第一附属医院 | 一种脑室-腹腔脑脊液分流管分流量检测装置及检测方法 |
| US11517653B2 (en) * | 2019-11-05 | 2022-12-06 | Diality Inc. | Hemodialysis system reservoir level sensor |
| CN111199781B (zh) * | 2019-12-30 | 2023-05-26 | 深圳市中医院 | 一种基于腹膜透析的诊疗数据自动标记方法 |
| CN112933316B (zh) * | 2021-02-04 | 2024-10-15 | 青岛大学附属医院 | 一种血液透析装置 |
| RU2765741C1 (ru) * | 2021-02-26 | 2022-02-02 | Общество с ограниченной ответственностью "Многопрофильный ветеринарный центр "Пёс и Кот" (ООО МВЦ "Пёс и Кот") | Способ гемодиализа у собак весом 8 и более кг |
| CN114618036A (zh) * | 2022-03-02 | 2022-06-14 | 佛山复星禅诚医院有限公司 | 一种血液透析a液质量监测系统 |
| WO2024043193A1 (ja) * | 2022-08-23 | 2024-02-29 | フィジオロガス・テクノロジーズ株式会社 | 対象液処理装置 |
| US11986584B1 (en) | 2023-02-20 | 2024-05-21 | Nuwellis, Inc. | Extracorporeal blood filtering machine and methods |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2162344C1 (ru) * | 1999-12-29 | 2001-01-27 | Санкт-Петербургская государственная педиатрическая медицинская академия | Способ проведения плазмосорбции |
| EP2019296A1 (en) * | 2006-04-14 | 2009-01-28 | Jms Co., Ltd. | Weight sensor and balance controller |
| WO2009071103A1 (en) * | 2007-12-03 | 2009-06-11 | Hepa Wash Gmbh | Dialysate regeneration unit |
| US20130087210A1 (en) * | 2010-06-14 | 2013-04-11 | Fresenius Medical Care Deutschland Gmbh | Method and device for conveying fluids into the treatment unit of a medical treatment apparatus, in particular into the dialyzer of a dialysis apparatus |
| WO2013144793A1 (en) * | 2012-03-28 | 2013-10-03 | Gambro Lundia Ab | Apparatus for extracorporeal treatment of blood |
| WO2014160370A1 (en) * | 2013-03-13 | 2014-10-02 | Nxstage Medical, Inc. | Single pass dialysis combined with multiple pass albumin dialysis |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4375414A (en) | 1971-05-20 | 1983-03-01 | Meir Strahilevitz | Immunological methods for removing species from the blood circulatory system and devices therefor |
| US3846236A (en) | 1971-10-22 | 1974-11-05 | Wisconsin Alumni Res Found | Method and apparatus for dialysis |
| SE7403799L (enExample) | 1974-03-21 | 1975-09-22 | Gambro Ab | |
| DE3230540A1 (de) | 1982-08-17 | 1984-02-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., 8000 München | Verfahren und vorrichtung zur entfernung von protein- oder lipidgebundenen toxinen aus blut oder blutfraktionen |
| US4663049A (en) | 1984-07-05 | 1987-05-05 | University Of Utah | Process for therapeutic dissociation of immune complexes and removal of antigens |
| IT8504923V0 (it) * | 1985-06-07 | 1985-06-07 | Miren Srl | Dispositivo per il controllo del bilancio idrico di un paziente durante il trattamento di emodialisi |
| FR2651438A1 (fr) | 1989-09-07 | 1991-03-08 | Fondation Nale Transfusion San | Procede d'inactivation par ultrasons d'agents infectieux ou parasitaires dans des milieux biologiques et applications du procede. |
| DE4309410A1 (de) | 1993-03-19 | 1995-02-16 | Stange Jan | Material, Verfahren und Einrichtung zur selektiven Trennung frei gelöster und stoffgebundener Stoffe aus flüssigen Stoffgemischen sowie Verfahren zur Herstellung des Materials |
| US5753227A (en) | 1993-07-23 | 1998-05-19 | Strahilevitz; Meir | Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases |
| US5561115A (en) | 1994-08-10 | 1996-10-01 | Bayer Corporation | Low temperature albumin fractionation using sodium caprylate as a partitioning agent |
| ATE283712T1 (de) | 1998-01-23 | 2004-12-15 | Viacirq Inc | Vorrichtung und verfahren zur ganzkörper- hyperthermiebehandlung |
| JP4061775B2 (ja) | 1998-05-21 | 2008-03-19 | ニプロ株式会社 | アルブミン含有腹膜透析液 |
| JP2000072658A (ja) | 1998-06-17 | 2000-03-07 | Nissho Corp | 腹膜透析液および腹膜透析法 |
| EP0980685B1 (en) | 1998-06-17 | 2006-01-25 | Nipro Corporation | Use of a fluid for the manufacture of a dialysis fluid for continuous recirculating peritoneal dialysis |
| DE19831061A1 (de) | 1998-07-10 | 2000-01-13 | Rotkreuzstiftung Zentrallab | Herstellung von Proteinpräparationen mit verringertem Aggregatgehalt |
| US7670491B2 (en) | 1998-10-20 | 2010-03-02 | Advanced Renal Technologies | Buffered compositions for dialysis |
| WO2001051184A1 (en) | 2000-01-11 | 2001-07-19 | Nephros, Inc. | Ionic enhanced dialysis/diafiltration system |
| US6716356B2 (en) | 2000-01-11 | 2004-04-06 | Nephros, Inc. | Thermally enhanced dialysis/diafiltration system |
| US7300674B2 (en) | 2000-12-20 | 2007-11-27 | Sheldon Tobe | Sterile low bicarbonate dialysis concentrate solutions |
| US7241272B2 (en) | 2001-11-13 | 2007-07-10 | Baxter International Inc. | Method and composition for removing uremic toxins in dialysis processes |
| US7455771B2 (en) | 2002-05-14 | 2008-11-25 | Hepa Wash Gmbh | Means for removing protein-bound substances |
| EP1362605A1 (de) | 2002-05-14 | 2003-11-19 | Bernhard Dr. Kreymann | Dialysevorrichtung zur Entfernung proteingebundener Substanzen |
| US7112273B2 (en) | 2002-09-27 | 2006-09-26 | Nxstage Medical, Inc. | Volumetric fluid balance control for extracorporeal blood treatment |
| US7686778B2 (en) | 2003-01-15 | 2010-03-30 | Nxstage Medical, Inc. | Waste balancing for extracorporeal blood treatment systems |
| ITMI20030212A1 (it) | 2003-02-07 | 2004-08-08 | Gambro Lundia Ab | Metodo per il trattamento extracorporeo di sangue |
| US7169303B2 (en) * | 2003-05-28 | 2007-01-30 | Hemocleanse Technologies, Llc | Sorbent reactor for extracorporeal blood treatment systems, peritoneal dialysis systems, and other body fluid treatment systems |
| EP1691863B1 (en) * | 2003-10-13 | 2008-02-20 | Gambro Lundia AB | A device for carrying out a peritoneal dialysis treatment |
| US7744553B2 (en) * | 2003-12-16 | 2010-06-29 | Baxter International Inc. | Medical fluid therapy flow control systems and methods |
| JP4903583B2 (ja) | 2003-12-24 | 2012-03-28 | ケミカ テクノロジーズ， インコーポレイテッド | 携帯式個人透析用透析液再生システム |
| EP1649883A1 (en) | 2004-10-19 | 2006-04-26 | MRI S.r.l. Società Unipersonale | A CO2 removal device for removing carbon dioxide from blood or from a fluid taken from patient's cardio-circulatory system |
| CN100444906C (zh) * | 2005-03-11 | 2008-12-24 | 暨南大学 | 一种液体平衡供液装置及其应用 |
| CN2824949Y (zh) * | 2005-06-17 | 2006-10-11 | 缪志俊 | 一种体外分子吸附循环系统 |
| CN100493632C (zh) * | 2006-08-25 | 2009-06-03 | 重庆山外山科技有限公司 | 血液净化用称重平衡系统 |
| CN101502682B (zh) * | 2006-08-25 | 2010-09-01 | 重庆山外山科技有限公司 | 血液净化用质量平衡系统 |
| DE102009008601A1 (de) | 2009-02-12 | 2010-08-19 | Novalung Gmbh | Vorrichtung zur Behandlung einer biologischen Flüssigkeit |
| CN101708347B (zh) * | 2009-03-11 | 2013-02-20 | 重庆多泰医用设备有限公司 | 由称重控制电导和超滤的血液透析系统 |
| PL2416770T3 (pl) | 2009-04-06 | 2017-06-30 | Crearene Ltd. | Roztwory do hemodializy i dializy otrzewnowej zawierające jeden lub więcej związków kreatyny |
| DK177144B1 (en) | 2009-06-19 | 2012-02-06 | Aquaporin As | A liquid membrane suitable for water extraction |
| JP5079747B2 (ja) * | 2009-06-24 | 2012-11-21 | 株式会社ジェイ・エム・エス | 重量計測装置 |
| JP2012228285A (ja) | 2011-04-23 | 2012-11-22 | Sunceramics Corp | 酸素濃度を高めた透析液 |
| EP2653178A1 (de) | 2012-04-16 | 2013-10-23 | Zentrum für biomedizinische Technologie der Donau- Universität Krems | Sicherheitseinrichtung für eine extrakorporale Blutbehandlung |
| GB201207543D0 (en) | 2012-05-01 | 2012-06-13 | Haemair Ltd | Treatment of transfusion blood |
| CN102940886B (zh) | 2012-12-13 | 2015-02-18 | 鼎正动物药业（天津）有限公司 | 一种生物屏障渗透剂及其制备方法 |
| US10322221B2 (en) | 2013-01-18 | 2019-06-18 | University of Pittsburgh—of the Commonwealth System of Higher Education | Removal of carbon dioxide via dialysis |
| CN103263704B (zh) * | 2013-05-09 | 2015-10-28 | 浙江大学 | 配备储浆袋的血浆置换吸附滤过净化系统 |
| US9646606B2 (en) | 2013-07-03 | 2017-05-09 | Google Inc. | Speech recognition using domain knowledge |
| DE102013019356A1 (de) | 2013-11-19 | 2015-06-03 | Fresenius Medical Care Deutschland Gmbh | Vorrichtung und Verfahren zum Bilanzieren von Flüssigkeiten für eine extrakorporale Blutbehandlungsvorrichtung |
| WO2017084682A1 (en) | 2015-11-20 | 2017-05-26 | Hepa Wash Gmbh | Method for extracorporeal carbon dioxide removal |
| WO2017084683A1 (en) | 2015-11-20 | 2017-05-26 | Hepa Wash Gmbh | Method for extracorporeal lung support |
| EP3634530B1 (en) | 2017-05-22 | 2025-07-02 | ADVITOS GmbH | Methods and systems for removing carbon dioxide |
-
2016
- 2016-03-14 DK DK16713981.5T patent/DK3429657T3/da active
- 2016-03-14 ES ES16713981T patent/ES2922636T3/es active Active
- 2016-03-14 PL PL16713981.5T patent/PL3429657T3/pl unknown
- 2016-03-14 JP JP2018548367A patent/JP7011263B2/ja active Active
- 2016-03-14 WO PCT/IB2016/000287 patent/WO2017158392A1/en not_active Ceased
- 2016-03-14 KR KR1020187028159A patent/KR20180125489A/ko not_active Ceased
- 2016-03-14 CA CA3017435A patent/CA3017435A1/en active Pending
- 2016-03-14 MX MX2018010947A patent/MX2018010947A/es unknown
- 2016-03-14 AU AU2016398366A patent/AU2016398366B2/en not_active Ceased
- 2016-03-14 RU RU2018135326A patent/RU2729725C2/ru active
- 2016-03-14 US US16/084,477 patent/US11351291B2/en active Active
- 2016-03-14 CN CN201680084889.3A patent/CN109069719B/zh not_active Expired - Fee Related
- 2016-03-14 EP EP16713981.5A patent/EP3429657B1/en active Active
-
2018
- 2018-09-05 IL IL261628A patent/IL261628B/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2162344C1 (ru) * | 1999-12-29 | 2001-01-27 | Санкт-Петербургская государственная педиатрическая медицинская академия | Способ проведения плазмосорбции |
| EP2019296A1 (en) * | 2006-04-14 | 2009-01-28 | Jms Co., Ltd. | Weight sensor and balance controller |
| WO2009071103A1 (en) * | 2007-12-03 | 2009-06-11 | Hepa Wash Gmbh | Dialysate regeneration unit |
| US20130087210A1 (en) * | 2010-06-14 | 2013-04-11 | Fresenius Medical Care Deutschland Gmbh | Method and device for conveying fluids into the treatment unit of a medical treatment apparatus, in particular into the dialyzer of a dialysis apparatus |
| WO2013144793A1 (en) * | 2012-03-28 | 2013-10-03 | Gambro Lundia Ab | Apparatus for extracorporeal treatment of blood |
| WO2014160370A1 (en) * | 2013-03-13 | 2014-10-02 | Nxstage Medical, Inc. | Single pass dialysis combined with multiple pass albumin dialysis |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2832055C2 (ru) * | 2021-07-14 | 2024-12-18 | Цзянсу Стмед Текнолоджи Ко., Лтд. | Мембранный оксигенатор |
| RU225627U1 (ru) * | 2023-12-30 | 2024-04-26 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Устройство контура доставки газовоздушной смеси с оксидом азота для аппаратов искусственного кровообращения |
Also Published As
| Publication number | Publication date |
|---|---|
| IL261628A (en) | 2018-10-31 |
| JP7011263B2 (ja) | 2022-01-26 |
| US11351291B2 (en) | 2022-06-07 |
| RU2018135326A (ru) | 2020-04-15 |
| AU2016398366A1 (en) | 2018-09-27 |
| MX2018010947A (es) | 2019-08-14 |
| JP2019509121A (ja) | 2019-04-04 |
| US20190192757A1 (en) | 2019-06-27 |
| AU2016398366B2 (en) | 2022-04-14 |
| DK3429657T3 (da) | 2022-06-13 |
| IL261628B (en) | 2022-05-01 |
| ES2922636T3 (es) | 2022-09-19 |
| PL3429657T3 (pl) | 2022-08-22 |
| KR20180125489A (ko) | 2018-11-23 |
| CN109069719A (zh) | 2018-12-21 |
| CA3017435A1 (en) | 2017-09-21 |
| EP3429657B1 (en) | 2022-05-18 |
| RU2018135326A3 (enExample) | 2020-04-15 |
| CN109069719B (zh) | 2021-11-26 |
| EP3429657A1 (en) | 2019-01-23 |
| WO2017158392A1 (en) | 2017-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2729725C2 (ru) | Системы или устройства и способы проведения диализа | |
| US20250161543A1 (en) | Modular hemodialysis system | |
| US20200306439A1 (en) | Hemodialysis system having a flow path with a controlled compliant volume | |
| EP2747808B1 (en) | Dual flow sorbent cartridge | |
| US20130256227A1 (en) | Polystyrene sulfonate resin for use with a hemodialysis system having a controlled compliance dialysis circuit | |
| US20140158588A1 (en) | pH AND BUFFER MANAGEMENT SYSTEM FOR HEMODIALYSIS SYSTEMS | |
| WO2016205221A1 (en) | System and method for extracorporeal blood treatment | |
| BR112015014618B1 (pt) | Aparelho para hemodiafiltração | |
| US11904083B2 (en) | Treatment aspects for reducing the carbon dioxide content in the blood |